Skip to main content
. Author manuscript; available in PMC: 2018 Jul 6.
Published in final edited form as: Birth Defects Res A Clin Mol Teratol. 2009 Jul;85(7):621–628. doi: 10.1002/bdra.20573

Table 5.

Association of Maternal Periconceptionala Antithyroid Medication Use with Selected Birth Defects,b National Birth Defects Prevention Study, 1997–2004

Antithyroid medication use/unexposed Crude OR (exact 95% CI)
Controls 5/5764 1.0
LVOTO CHDsc 4/972 4.7 (0.9–22.1)
Aortic valve stenosis 3/157 22.0 (3.4–114.0)
Septal CHDsc 3/2526 1.4 (0.2–7.0)
Anorectal atresia 4/534 8.6 (1.7–40.2)
a

During the period one month before conception through the end of the first trimester.

b

Among all 14,067 cases combined, 20 mothers reported peri-conceptional antithyroid medication use. Five of 5769 control mothers reported periconceptional antithyroid medication use. All 42 birth defect categories were examined (total cases, not restricted to isolated defects); results are presented only for birth defect categories with three or more exposed cases.

c

Only simple congenital heart defects and common associations are included. LVOTO associations include coarctation of the aorta + aortic stenosis, coarctation of the aorta + VSD, co-arctation of the aorta + VSD + ASD. Septal associations include VSD + ASD.

OR, odds ratio; CI, confidence interval; LVOTO, left ventricular outflow tract obstruction; CHD, congenital heart defect.